Silence, AstraZeneca Form siRNA Delivery Tech Collaboration
Silence Therapeutics and AstraZeneca last week announced they have formed a new collaboration focused on developing novel siRNA delivery approaches.
The deal, according to the companies, is independent of their 2007 arrangement under which Silence granted a license to AstraZeneca to use its proprietary siRNA technology to develop RNAi drugs against five undisclosed targets (see RNAi News, 7/12/2007).
Under the newest deal, the companies will each be allowed to commercialize drugs using the delivery systems they develop together.
Additional terms were not disclosed.
Alnylam Licenses RNAi IP to China’s Shanghai GenePharma
Alnylam Pharmaceuticals this week said it has granted a non-exclusive, worldwide license to its Kreutzer-Limmer patent family to Chinese reagent shop Shanghai GenePharma for manufacturing and marketing RNAi research products and services.
The patents, according to Alnylam, cover fundamental aspects of the structure and uses of RNAi products, including their use to mediate RNAi in mammalian cells and of RNAi-related mechanisms.
"Providing this license to Shanghai GenePharma represents our first business transaction in China,” Jason Rhodes, vice president of business development at Alnylam, said in a statement.
Specific terms of the license were not disclosed.
Cenix to Perform High-Throughput RNAi Screens for AstraZeneca, CellCentric
Cenix Bioscience this week said it has signed deals to conduct high-throughput RNAi screening experiments for drug maker AstraZeneca and British epigenetics firm CellCentric.
Under the first deal, Cenix will perform a high-throughput RNAi screen, using an assay strategy developed with AstraZeneca researchers, to discover and validate new oncology targets.
The second agreement calls for Cenix to use its high-throughput RNAi screening technology to validate several anti-cancer drug targets selected by CellCentric.
Additional terms of the arrangements were not disclosed.